Inspra Related Published Studies
Well-designed clinical trials related to Inspra (Eplerenone)
Effect of eplerenone in percutaneous coronary intervention-treated
post-myocardial infarction patients with left ventricular systolic dysfunction: a
subanalysis of the EPHESUS trial. [2014]
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. [2011.05]
Eplerenone in patients with systolic heart failure and mild symptoms. [2011.01.06]
Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions. [2011]
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. [2010.11]
The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. [2010.08]
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). [2010.06]
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. [2010.06]
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. [2010.05]
A population approach to eplerenone pharmacokinetics and saturable protein binding. [2010]
The efficacy and safety of the novel aldosterone antagonist eplerenone in
children with hypertension: a randomized, double-blind, dose-response study. [2010]
Rationale and design of the Eplerenone in Mild Patients Hospitalization And
SurvIval Study in Heart Failure (EMPHASIS-HF). [2010]
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. [2009.11]
Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. [2009.10.27]
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. [2009.09]
Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? [2009.06]
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. [2009.05.12]
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). [2009.01.27]
Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. [2008.09]
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. [2008.08]
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. [2008.08]
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. [2008.03]
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. [2008.02]
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. [2006.09]
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. [2006.05]
Effects of eplerenone versus losartan in patients with low-renin hypertension. [2005.09]
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. [2005.08.02]
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. [2005.03.08]
Distinguishing the antihypertensive and electrolyte effects of eplerenone. [2004.06]
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. [2004.04.15]
Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. [2004.04]
Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? [2003.11]
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. [2003.10.14]
Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. [2003.07.01]
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. [2003.05]
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. [2003.04.03]
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. [2003.04.02]
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. [2002.08]
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. [2002.08]
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). [2002.04]
Well-designed clinical trials possibly related to Inspra (Eplerenone)
Magnitude of blood pressure reduction in the placebo arms of modern hypertension
trials: implications for trials of renal denervation. [2015]
Rationale and design of a randomized trial on the impact of aldosterone
antagonism on cardiac structure and function in diabetic cardiomyopathy. [2013]
Statin therapy and clinical outcomes in myocardial infarction patients
complicated by acute heart failure: insights from the EPHESUS trial. [2013]
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. [2011.11.01]
Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). [2011.08]
Clinical Trials Update AHA Congress 2010. [2011.02]
Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. [2010.07.01]
Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. [2010.07]
Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age. [2010.06]
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction. [2010.05]
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. [2010.01.19]
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). [2009.06.01]
Plasma apelin concentration is depressed following acute myocardial infarction in man. [2009.06]
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction. [2009.05.15]
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. [2009.02]
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ] [2009]
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. [2008.12.09]
Aldosterone antagonists : the most underutilized class of heart failure medications. [2007]
RALES, EPHESUS and redox. [2005.02]
Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. [2004.07]
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. [2003.07.14]
Other research related to Inspra (Eplerenone)
Everolimus in combination with exemestane: a review of its use in the treatment
of patients with postmenopausal hormone receptor-positive, HER2-negative advanced
breast cancer. [2013]
The impact of eplerenone at different levels of risk in patients with systolic
heart failure and mild symptoms: insight from a novel risk score for prognosis
derived from the EMPHASIS-HF trial. [2013]
Eplerenone and new-onset diabetes in patients with mild heart failure: results
from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart
Failure (EMPHASIS-HF). [2012]
Mineralocorticoid receptor blocker eplerenone improves endothelial function and
inhibits Rho-associated kinase activity in patients with hypertension. [2012]
Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report. [2011.10.18]
Protective effects of eplerenone on podocyte injury in adriamycin nephropathy rats. [2011.06]
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. [2011.03]
Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. [2011]
Review article: eplerenone: an underused medication? [2010.12]
The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat. [2010.06]
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. [2010.06]
Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. [2010.05]
Eplerenone improves vascular function and reduces platelet activation in diabetic rats. [2010.02]
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. [2010]
Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty. [2010]
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats. [2010]
Rationale and design of the Eplerenone combination Versus conventional Agents to
Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE)
trial: a double-blinded randomized placebo-controlled trial to evaluate the
antialbuminuric effects of an aldosterone blocker in hypertensive patients with
albuminuria. [2010]
Randomized, double-blind, multicenter, placebo-controlled study evaluating the
effect of aldosterone antagonism with eplerenone on ventricular remodeling in
patients with mild-to-moderate heart failure and left ventricular systolic
dysfunction. [2010]
Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. [2009.05]
Anti-inflammatory effects of eplerenone on viral myocarditis. [2009.04]
The clinical pharmacology of eplerenone. [2009.04]
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. [2009.01]
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). [2008.10.14]
Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. [2008.09]
Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. [2008.09]
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. [2008.06]
A comparison of the aldosterone-blocking agents eplerenone and spironolactone. [2008.04]
Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. [2008.03]
Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone. [2008.02]
Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. [2008.01]
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. [2007.12]
Effect of Long-term Monotherapy with the Aldosterone Receptor Blocker Eplerenone on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure. [2007.12]
Effect of Long-term Monotherapy with the Aldosterone Receptor Blocker Eplerenone on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure. [2007.10.17]
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. [2007.07]
Beneficial Effects of Eplerenone Versus Hydrochlorothiazide on Coronary Circulatory Function in Patients with Diabetes Mellitus. [2007.05.08]
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. [2007.05]
Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats. [2007.01.02]
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. [2006.08]
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. [2006.06]
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. [2006.04]
|